Michael Floyd - 01 Nov 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Chief Operating Officer
Signature: /s/ Michael Floyd by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 01 Nov 2021
Transactions value $: $0
Form type: 4
Filing time: 04 Apr 2022, 17:50:31 UTC
Previous filing: 08 Oct 2021
Next filing: 06 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Gift	$0	-7,000	-9%	$0	70,930	31 Mar 2022	Direct	F1
holding	PCSA	Common Stock						66,345	01 Nov 2021	by Elion Oncology, Inc.	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCSA	Restricted Stock Units	Award	$0	+4,286	+19%	$0	27,066	01 Nov 2021	Common Stock	4,286	$0	Direct	F2
transaction	PCSA	Restricted Stock Units	Award	$0	+10,715	+40%	$0	37,781	31 Mar 2022	Common Stock	10,715	$0	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in an transaction exempt from Section 16 reporting.
F2	Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.